Selected Articles from This Issue

2021 Molecular Cancer Therapeutics  
Dysregulation of the protein arginine methyltransferase 5 (PRMT5) is associated with lymphomas, lung cancers, and breast cancers. In this First Disclosure, Brehmer and colleagues outline JNJ-64619178, an inhibitor of PRMT5 with potent anti-proliferative activity. JNJ-64619178 occupies the SAM and substrate pockets of PRMT5, trapping it in a catalytically inactive state. PMRT5 inhibition by JNJ-64619178 increased alternatively spliced events and resulted in the killing of primary AML samples ex
more » ... ivo. Taken together, the results support the continued clinical study of JNJ-64619178 (NCT03573310).
doi:10.1158/1535-7163.mct-20-12-hi pmid:34862328 fatcat:vn4yeg7ugjeghojqmislw5do7m